Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chadi Nabhan

Showing results (81-90 of 199) with videos related to

Pageof 20
Sort By:
Oncology (Williston Park, N.Y.)|March 28, 2013
Diffuse large B-cell non-Hodgkin lymphoma in the very elderly: challenges and solutionsShadi Latta, Peter H Cygan, Walter Fried, et al.
Leukemia & Lymphoma|February 18, 2011
Biologic agent activity in chronic lymphocytic leukemia: a framework for future therapiesChadi Nabhan, Neil Dalal, Jayesh Mehta, et al.
Cancer Treatment and Research|November 30, 2022
Biosimilar Epoetin in the United States: A View from the Southern Network on Adverse ReactionsSumimasa Nagai, Bartlett Witherspoon, Chadi Nabhan, et al.
The American Journal of Managed Care|March 17, 2017
CAR-T cells: the next era in immuno-oncologyBruce A Feinberg, Jennifer Fillman, Justin Simoncini, et al.
JCO Precision Oncology|February 17, 2022
Real-World Evidence and Randomized Studies in the Precision Oncology Era: The Right BalanceBishal Gyawali, Sandeep Parsad, Bruce A Feinberg, et al.
Leukemia & Lymphoma|November 10, 2011
Cutaneous involvement with B-lineage acute lymphoblastic leukemiaChadi Nabhan, Angelica Tolentino, Andrew Meyer, et al.
JAMA Oncology|July 21, 2017
Biosimilars in Oncology in the United States: A ReviewChadi Nabhan, Sandeep Parsad, Anthony R Mato, et al.
Leukemia & Lymphoma|July 15, 2016
Ofatumumab monotherapy in relapsed/refractory diffuse large B-cell non-Hodgkin lymphomaNatalie Galanina, Jagoda Jasielec, David Peace, et al.
Blood|January 25, 2002
Acute promyelocytic leukemia: evolving therapeutic strategiesMartin S Tallman, Chadi Nabhan, James H Feusner, et al.
Translational Oncology|June 25, 2021
Response to "The need for validation of MI GPSai in patients with CUP: Comment on: "Machine learning analysis using 77,044 genomic and transcriptomic profiles to accurately predict tumor type" by J Abraham et al."Jim Abraham, Chadi Nabhan, Matthew Oberley, et al.
Pageof 20

Showing results (81-90 of 199) with videos related to

Sort By:
Pageof 20
Oncology (Williston Park, N.Y.)|March 28, 2013
Diffuse large B-cell non-Hodgkin lymphoma in the very elderly: challenges and solutionsShadi Latta, Peter H Cygan, Walter Fried, et al.
Leukemia & Lymphoma|February 18, 2011
Biologic agent activity in chronic lymphocytic leukemia: a framework for future therapiesChadi Nabhan, Neil Dalal, Jayesh Mehta, et al.
Cancer Treatment and Research|November 30, 2022
Biosimilar Epoetin in the United States: A View from the Southern Network on Adverse ReactionsSumimasa Nagai, Bartlett Witherspoon, Chadi Nabhan, et al.
The American Journal of Managed Care|March 17, 2017
CAR-T cells: the next era in immuno-oncologyBruce A Feinberg, Jennifer Fillman, Justin Simoncini, et al.
JCO Precision Oncology|February 17, 2022
Real-World Evidence and Randomized Studies in the Precision Oncology Era: The Right BalanceBishal Gyawali, Sandeep Parsad, Bruce A Feinberg, et al.
Leukemia & Lymphoma|November 10, 2011
Cutaneous involvement with B-lineage acute lymphoblastic leukemiaChadi Nabhan, Angelica Tolentino, Andrew Meyer, et al.
JAMA Oncology|July 21, 2017
Biosimilars in Oncology in the United States: A ReviewChadi Nabhan, Sandeep Parsad, Anthony R Mato, et al.
Leukemia & Lymphoma|July 15, 2016
Ofatumumab monotherapy in relapsed/refractory diffuse large B-cell non-Hodgkin lymphomaNatalie Galanina, Jagoda Jasielec, David Peace, et al.
Blood|January 25, 2002
Acute promyelocytic leukemia: evolving therapeutic strategiesMartin S Tallman, Chadi Nabhan, James H Feusner, et al.
Translational Oncology|June 25, 2021
Response to "The need for validation of MI GPSai in patients with CUP: Comment on: "Machine learning analysis using 77,044 genomic and transcriptomic profiles to accurately predict tumor type" by J Abraham et al."Jim Abraham, Chadi Nabhan, Matthew Oberley, et al.
Pageof 20